Coronavirus: great hope for the next deployment of the Oxford/AstraZeneca vaccine candidate

  •   09/11/2020 - 09h21
  •   DEHOUI Lionel

To eradicate the coronavirus pandemic, the development of a vaccine appears to be a plausible solution. Thus,Oxford University and AstraZeneca have joined forces to develop a candidate vaccine against Covid-19. However, the University is optimistic that the results of advanced trials of this vaccine will be published soon.

--- Advertisement ---
Trade Astrazeneca shares!
76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
Coronavirus: great hope for the next deployment of the Oxford/AstraZeneca vaccine candidate
Image copyright: Daniel Paquet

Announcement of the upcoming publication of results of the candidate vaccine trials

Oxford University remains optimistic that the results of the advanced trials of its vaccine candidate will be presented soon. It should be noted that the development of this vaccine to prevent Coronavirus stems from a collaboration between the university and the AstraZeneca group. Thus, the Oxford Graduate School hopes to publish these results before the end of this year.

The head of the Oxford Vaccine Group's vaccine research centre has not failed to comment on the subject. Indeed, Andrew Pollard addressed the British parliamentarians and expressed his optimism about the forthcoming presentation of the results of these clinical trials.

However, the man made this statement while expressing some reservations. It undoubtedly refers to a busy schedule that will have to be faced prior to the deployment of the candidate vaccine. Indeed, the immunology expert says: "Before the vaccine can be deployed, regulators will need to make a careful examination of data"

He also raises issues related to how the vaccine will be distributed and to whom it will be distributed, but believes that these issues should be addressed by the government before proceeding with a rollout of the candidate vaccine.

 

Upcoming deployment of Oxford/AstraZeneca's vaccine candidate: a hope to regulate the health crisis

The Coronavirus pandemic has been causing a lot of damage around the world for several months now. This epidemic has caused more than 1.2 million deaths worldwide. It has also paralyzed several sectors, pioneers of the global economy. While a cure is still a long way off, there is undoubtedly hope for the development of a vaccine.

Indeed, many studies and research are being carried out by scientists around the world to develop a vaccine against this disease. The arrival of the Oxford/AstraZeneca candidate vaccine is therefore good news that gives hope for the eradication of this epidemic.

Its finalization will undoubtedly favour a stabilization of the current situation and a return to a certain normality after several months of crisis. In addition, Boris Johnson has given his opinion on a possible date when a vaccine could be deployed against Covid-19.

Indeed, the British Prime Minister made a statement in which he mentioned that a deployment will be possible in the first quarter of 2021.

 

About the Oxford/AstraZeneca Vaccine Candidate

Studies for the development of the University's vaccine candidate have been underway since last January. This vaccine is designated "AZD1222 " or "ChAdOx1 nCoV-19". It is based on a chimpanzee adenovirus. The researchers therefore modified this adenovirus to insert the part with the code for the SARS-CoV-2 spike protein into the animal genome.

It should be noted that CAdOx1 nCoV-2 is the virus responsible for covid-19 and penetrates human cells. Also, the Oxford/AstraZeneca vaccine candidate is among the first vaccines to seek formal approval from regulatory authorities.